Our in vivo study provided that blocking HLA-G with a specific neutralizing antibody can inhibit the growth of HLA-G-positive tumor cells and restore antitumour immunity against HLA-G-positive tumor cells in a humanized mouse model of ovarian cancer (70). This evidence concerns the gene HLA-G and ovarian carcinoma.